http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-WO2005075492-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C63-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H15-203 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H15-203 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7034 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7036 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate | 2005-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2007-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-WO2005075492-A1 |
| titleOfInvention | Glycoside prodrugs of 5-aminosalicylic acid |
| abstract | An object of the present invention is to allow 5-aminosalicylic acid (5-ASA), which is useful as a therapeutic agent for ulcerative colitis, to reach the large intestine which is a disease site efficiently without being almost absorbed or metabolized in the stomach or upper small intestine. An object of the present invention is to provide a therapeutic agent for ulcerative colitis that can be administered safely and can be administered for a long time. The present invention relates to 5-ASA into which D-galactose represented by the following general formula [1] is introduced. The compound of the present invention can efficiently reach the large intestine, which is the site of action, and can be decomposed by the intestinal bacterial flora to produce 5-ASA as the active substance in the large intestine. |
| priorityDate | 2004-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 109.